EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Patient with Vulnerable Coronary Plaque and Treatment with Evolocumab: A Clinical Case

Lucio Addeo iD, Pasquale Guarini, Pasquale Campana, Luigi Argenziano, Stefano Nardi iD, Carlo Tedeschi, Alessandra Scatteia iD, Mattia Silvestre, Antonio Rapacciuolo iD, Giovanni Esposito, Salvatore Giordano iD, Laura Adelaide Dalla Vecchia iD und 1 weitere

Journal of Clinical Medicine · 14.02.2025 · 14 (4) · 1257

DOI: 10.3390/jcm14041257 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Clinical Medicine, online erschienen am 14.02.2025. Verfasst von Lucio Addeo und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Advanced Biomedical Sciences, University of Naples Federico II, Via Sergio Pansini, 80131 Naples, Italy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CardioPath program at Federico II University of Naples, Università degli Studi di Milano.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Vulnerable coronary plaques are strongly associated with acute coronary events, posing significant therapeutic challenges despite statin therapy. This case report evaluates the impact of Evolocumab, a PCSK-9 inhibitor, on stabilizing high-risk plaques and promoting phenotypic transformation, assessed through coronary CT angiography (CCTA).

Methods

A 50-year-old male with chronic coronary syndrome and a history of myocardial infarction underwent a CCTA, revealing a high-risk plaque (approximately 50%) in the proximal LAD. Despite achieving LDL-C targets with statin therapy, the plaque showed vulnerability features. Evolocumab (140 mg subcutaneously every two weeks) was added to therapy, combined with dietary counseling and dual antiplatelet therapy.

Results

A follow-up CCTA at 24 months demonstrated significant reductions in plaque volume and positive remodeling, with a transformation from a mixed phenotype to a predominantly calcified plaque. LDL-C levels decreased from 71 mg/dL to 18 mg/dL. The patient remained asymptomatic, with no cardiovascular events reported during the follow-up.

Conclusions

This case highlights the role of PCSK-9 inhibitors in stabilizing high-risk plaques, achieving structural changes that promote stability beyond LDL-C reduction. Advanced imaging techniques such as CCTA proved essential for risk stratification and monitoring therapy efficacy. Evolocumab offers a promising adjunctive treatment for high-risk patients unsuitable for elective revascularization, potentially redefining the standard of care for plaque stabilization in this setting.

Schlagwörter

Stichwörter der Autor:innen

PCSK-9 inhibitorscoronary CT angiographyplaque stabilization

Autor:innen und Institutionen

  • Department of Advanced Biomedical Sciences, University of Naples Federico II, Via Sergio Pansini, 80131 Naples, Italy.
  • U.O Cardiologia, Clinica Sanatrix, Centro Studi SICOA, 80127 Naples, Italy.
  • Dipartimento di Cardiologia, Pineta Grande Hospital, Castel Volturno, 81030 Caserta, Italy.
  • IRCCS SYNLAB SDN, Via Emanuele Gianturco 113, 80143 Naples, Italy.
  • Unità di Imaging Cardiovascolare Avanzato, Clinica Villa dei Fiori, Acerra, 80011 Naples, Italy.
  • Unità di Radiologia, Pineta Grande Hospital, Castel Volturno, 81030 Caserta, Italy.

ORCID-Profile: Lucio Addeo, Stefano Nardi, Alessandra Scatteia, Antonio Rapacciuolo, Salvatore Giordano, Laura Adelaide Dalla Vecchia, Francesco Donatelli

Förderung

  • CardioPath program at Federico II University of Naples
  • Università degli Studi di Milano

Zitieren

APA

Addeo, L., Guarini, P., Campana, P., Argenziano, L., Nardi, S., Tedeschi, C., Scatteia, A., Silvestre, M., Rapacciuolo, A., Esposito, G., Giordano, S., Dalla Vecchia, L. A., & Donatelli, F. (2025). Patient with Vulnerable Coronary Plaque and Treatment with Evolocumab: A Clinical Case. Journal of Clinical Medicine, 14(4), 1257. https://doi.org/10.3390/jcm14041257

Vancouver

Addeo L, Guarini P, Campana P, Argenziano L, Nardi S, Tedeschi C, et al. Patient with Vulnerable Coronary Plaque and Treatment with Evolocumab: A Clinical Case. Journal of Clinical Medicine. 2025;14(4):1257. doi:10.3390/jcm14041257

BibTeX
@article{Addeo2025,
  author = {Addeo, Lucio and Guarini, Pasquale and Campana, Pasquale and Argenziano, Luigi and Nardi, Stefano and Tedeschi, Carlo and Scatteia, Alessandra and Silvestre, Mattia and Rapacciuolo, Antonio and Esposito, Giovanni and Giordano, Salvatore and Dalla Vecchia, Laura Adelaide and Donatelli, Francesco},
  title = {Patient with Vulnerable Coronary Plaque and Treatment with Evolocumab: A Clinical Case},
  journal = {Journal of Clinical Medicine},
  year = {2025},
  volume = {14},
  number = {4},
  pages = {1257},
  doi = {10.3390/jcm14041257}
}
Kostenlos starten →